MA52924A - Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule - Google Patents

Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule

Info

Publication number
MA52924A
MA52924A MA052924A MA52924A MA52924A MA 52924 A MA52924 A MA 52924A MA 052924 A MA052924 A MA 052924A MA 52924 A MA52924 A MA 52924A MA 52924 A MA52924 A MA 52924A
Authority
MA
Morocco
Prior art keywords
combinations
topical formulations
formulations including
adhesion proteins
mold adhesion
Prior art date
Application number
MA052924A
Other languages
English (en)
Inventor
Ming Gu
Bengt Ingemar Samuelsson
Original Assignee
Jiangyin Mucocare Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangyin Mucocare Pharmaceutical Co Ltd filed Critical Jiangyin Mucocare Pharmaceutical Co Ltd
Publication of MA52924A publication Critical patent/MA52924A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
MA052924A 2017-07-05 2018-07-04 Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule MA52924A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2017091819 2017-07-05
CN2018087058 2018-05-16

Publications (1)

Publication Number Publication Date
MA52924A true MA52924A (fr) 2021-04-28

Family

ID=64949737

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052924A MA52924A (fr) 2017-07-05 2018-07-04 Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule

Country Status (12)

Country Link
US (2) US11672792B2 (fr)
EP (1) EP3648767A4 (fr)
JP (1) JP7288404B2 (fr)
KR (1) KR20200039677A (fr)
CN (3) CN113491696A (fr)
AU (1) AU2018295944B2 (fr)
CA (1) CA3068818A1 (fr)
MA (1) MA52924A (fr)
MX (1) MX2020000029A (fr)
SG (1) SG11201911841PA (fr)
TW (1) TW201919633A (fr)
WO (1) WO2019007356A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113491696A (zh) * 2017-07-05 2021-10-12 江阴优培尔康药业有限公司 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
AU2019338582A1 (en) * 2018-09-14 2020-11-19 Jiangyin Usun Pharmaceutical Co., Ltd. New conjugates of montelukast and peptides
CN113613657A (zh) * 2019-01-10 2021-11-05 江阴优培尔康药业有限公司 含有白三烯受体拮抗剂的新型配制品
AU2020344762A1 (en) * 2019-09-14 2022-04-14 Jiangyin Usun Pharmaceutical Co., Ltd. New peptides
WO2021110064A1 (fr) * 2019-12-02 2021-06-10 Jiangyin Usun Biochemical Technology Co., Ltd. Nouveaux oligopeptides multifonctionnels
WO2021110063A1 (fr) * 2019-12-02 2021-06-10 Jiangyin Usun Biochemical Technology Co., Ltd. Nouveaux conjugués de peptides et de polysaccharide
US11173117B2 (en) 2020-02-03 2021-11-16 Taro Pharmaceutical Industries Ltd. Topical Montelukast formulations
EP4228641A1 (fr) 2020-10-13 2023-08-23 Diomed Developments Limited Formulations de gel contenant du montélukast
CN114588267A (zh) * 2020-12-04 2022-06-07 江苏恒瑞医药股份有限公司 一种含酰胺类局部麻醉药的药物组合物
WO2022193186A1 (fr) * 2021-03-17 2022-09-22 Jiangyin Usun Pharmaceutical Co., Ltd. Nouveaux agents diagnostiques et thérapeutiques
US20240165247A1 (en) * 2021-03-17 2024-05-23 Jiangyin Usun Pharmaceutical Co., Ltd. New peptide conjugates
CN117794539A (zh) * 2021-08-06 2024-03-29 艾缇亚(上海)制药有限公司 免疫缺陷障碍的新治疗
CN116421547A (zh) * 2023-03-09 2023-07-14 中国医学科学院皮肤病医院(中国医学科学院皮肤病研究所) 一种孟鲁司特钠外用乳膏剂的制备及其在炎症性皮肤病中的应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU224814B1 (en) * 1995-12-28 2006-02-28 Mitsubishi Pharma Corp Use of propane-1,3-diol derivative for the preparation of a medicament useful for the topical treating of inflammatory and immune diseases
US20030207932A1 (en) * 2002-05-03 2003-11-06 Morris Mann Compositions that prevent post-traumatic hyperpigmentation and methods related thereto
DK1651161T3 (da) * 2003-08-07 2012-01-30 Healor Ltd Farmaceutiske præparater og fremgangsmåder til at fremme sårheling
US6987170B1 (en) * 2004-08-09 2006-01-17 Battelle Energy Alliance, Llc Cloning and expression of recombinant adhesive protein Mefp-1 of the blue mussel, Mytilus edulis
WO2007126865A2 (fr) * 2006-03-30 2007-11-08 Patrin Pharma Administration nasale d'antagonistes de leukotriènes
CN1961867A (zh) * 2006-11-16 2007-05-16 徐英权 孟鲁司特钠的颗粒剂型
WO2008106081A1 (fr) * 2007-02-26 2008-09-04 Larry Schlesinger Formulations topiques contenant un antagoniste récepteur d'un leucotriène et leurs utilisations traiter ou prévenir la contracture capsulaire, la formation de cicatrice ou l'hyperpigmentation
WO2008105803A1 (fr) * 2007-02-26 2008-09-04 Larry Schlesinger Formulations topiques contenant un antagoniste du récepteur de leucotriène et utilisations associées
US20110124681A1 (en) * 2008-05-06 2011-05-26 Schlesinger Larry S Topical and injectable formulations comprising leukotriene receptor antagonist and uses thereof
CA2653011A1 (fr) * 2008-12-03 2010-06-03 Apotex Technologies Inc Appareil et procede d'emballage et de distribution de produits pharmaceutiques
GB0915319D0 (en) * 2009-09-03 2009-10-07 Sharma Anant Combination medicament
CN101773503A (zh) * 2010-01-12 2010-07-14 北京华禧联合科技发展有限公司 一种白三烯拮抗剂和抗组胺药组合物
KR101801864B1 (ko) 2010-06-16 2017-11-27 인플래머토리 리스폰스 리서치, 아이엔씨. 인플루엔자, 감기 및 염증의 치료에서 레보세티리진 및 몬테루카스트의 용도
CN102895661A (zh) * 2011-07-28 2013-01-30 中国科学院上海药物研究所 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途
JP6200432B2 (ja) 2011-12-26 2017-09-20 エスケー ケミカルズ カンパニー リミテッド モンテルカストまたはその薬学的に許容可能な塩を含む経口投与用フィルム
CN103239450B (zh) 2012-02-07 2014-11-26 齐鲁制药有限公司 一种能快速溶出、稳定的孟鲁司特钠口服固体制剂及其制备方法
RU2672871C2 (ru) * 2013-03-13 2018-11-20 Инфламматори Респонс Ресёрч, Инк. Применение левоцетиризина и монтелукаста при лечении травматических повреждений
CN103655497B (zh) * 2013-12-18 2018-05-29 北京华禧联合科技发展有限公司 一种孟鲁司特钠口腔崩解片及其制备方法
CN105769825A (zh) 2014-12-24 2016-07-20 广州朗圣药业有限公司 一种孟鲁司特钠的口腔膜剂及其制备方法
CN105878215A (zh) 2014-12-31 2016-08-24 天津康鸿医药科技发展有限公司 一种稳定的孟鲁司特口腔速溶膜及其制备方法和用途
KR101892340B1 (ko) * 2015-03-13 2018-08-27 경희대학교 산학협력단 몬테루카스트의 생체이용률을 개선시키기 위한 방법
CN104784157B (zh) 2015-04-04 2018-06-26 齐鲁制药有限公司 一种稳定的孟鲁司特口腔薄膜剂
WO2017011983A1 (fr) * 2015-07-20 2017-01-26 江阴市本特塞缪森生命科学研究院有限公司 Protéine de moule à action adhésive indiquée pour la protection cutanée et de l'appendice cutané
BR112018000953A2 (pt) * 2015-07-20 2018-09-11 Bengt I. Samuelsson Institute Of Life Science Research produto de proteína adesiva de mexilhão e aplicações do mesmo na supressão de inflamações de pele
JP6947756B2 (ja) * 2016-02-22 2021-10-13 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System 抗菌組成物およびその使用
US10548837B1 (en) 2016-05-04 2020-02-04 Taro Pharmaceutical Industries Ltd. Topical montelukast for treatment of atopic dermatitis
CN113491696A (zh) * 2017-07-05 2021-10-12 江阴优培尔康药业有限公司 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
KR20210016365A (ko) * 2018-05-28 2021-02-15 장인 우선 파마슈티컬 컴퍼니 리미티드 새로운 약제학적 용도
AU2019338582A1 (en) * 2018-09-14 2020-11-19 Jiangyin Usun Pharmaceutical Co., Ltd. New conjugates of montelukast and peptides
CN113613657A (zh) * 2019-01-10 2021-11-05 江阴优培尔康药业有限公司 含有白三烯受体拮抗剂的新型配制品

Also Published As

Publication number Publication date
JP7288404B2 (ja) 2023-06-07
EP3648767A4 (fr) 2021-04-28
MX2020000029A (es) 2020-08-06
US20230404992A1 (en) 2023-12-21
CN115300508A (zh) 2022-11-08
US20210145819A1 (en) 2021-05-20
TW201919633A (zh) 2019-06-01
CN110312513A (zh) 2019-10-08
CA3068818A1 (fr) 2019-01-10
JP2020527134A (ja) 2020-09-03
SG11201911841PA (en) 2020-01-30
CN113491696A (zh) 2021-10-12
CN110312513B (zh) 2022-07-08
AU2018295944B2 (en) 2023-12-14
US11672792B2 (en) 2023-06-13
WO2019007356A1 (fr) 2019-01-10
EP3648767A1 (fr) 2020-05-13
AU2018295944A1 (en) 2020-02-20
KR20200039677A (ko) 2020-04-16

Similar Documents

Publication Publication Date Title
MA52924A (fr) Formulations topiques comprenant du montélukast et combinaisons avec protéines d'adhérence de moule
MA49043A (fr) Formulation stable d'anticorps
MA45600A (fr) Stéroïdes neuroactifs substitués en c7, c12 et c16 et méthodes d'utilisation associées
MA46820A (fr) Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques
MA50746A (fr) Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
MA51903A (fr) Formulations d'anticorps b7-h4
EP3518971A4 (fr) Formulations thérapeutiques d'anticorps et de protéines et leurs utilisations
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
ZA202101250B (en) Novel crispr-associated protein and use thereof
MA53015A (fr) Anticorps anti-sirp-bêta1 et procédés d'utilisation associés
MA54139A (fr) Formulation d'anticorps
IL277007A (en) Therapeutic ANTI-SPLA2-GIB antibodies and their uses
MA43049A (fr) Anticorps de liaison à un récepteur cannabinoïde 1 humain (cb1)
ZA201907063B (en) Insecticidal proteins and methods for their use
EP3768836A4 (fr) Modèle animal de la maladie d'alzheimer et son utilisation
IL279178A (en) Weird Cas9 protein and its use
MA48442A (fr) Structure d'extérieur
MA45158A (fr) Composition pharmaceutique comprenant de l'éteplirsen
FR3037094B1 (fr) Chassis de dormant et/ou d'ouvrant
MA44859A (fr) Pseudodimères d'oxazoline, compositions pharmaceutiques et utilisation correspondantes
MA44010A (fr) Formulations pharmaceutiques de billes comprenant du diméthylfumarate
UA38939S (uk) Велобіг-мотоцикл дитячий
ITPD20150011U1 (it) Mutande da uomo con funzioni correttive e separative
JP1642785S (ja) 子供用いす
UA39605S (uk) Стілець учнівський